Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded down 2.8% during trading on Wednesday . The stock traded as low as $39.56 and last traded at $39.89, with a volume of 185,940 shares traded. The stock had previously closed at $41.04.

Several equities research analysts recently commented on the stock. Leerink Swann reiterated a “buy” rating and set a $95.00 target price on shares of Intra-Cellular Therapies in a research report on Thursday, August 11th. Cowen and Company reiterated a “buy” rating and set a $75.00 target price on shares of Intra-Cellular Therapies in a research report on Friday, August 5th. Piper Jaffray Cos. assumed coverage on shares of Intra-Cellular Therapies in a report on Wednesday, June 1st. They set an “overweight” rating and a $57.00 price target for the company. Finally, Zacks Investment Research lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Intra-Cellular Therapies presently has a consensus rating of “Buy” and a consensus target price of $70.78.

The company’s market capitalization is $1.77 billion. The firm’s 50 day moving average is $40.62 and its 200-day moving average is $34.86.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.08. The company earned $0.23 million during the quarter, compared to the consensus estimate of $0.02 million. During the same quarter last year, the company posted ($0.61) earnings per share. The firm’s revenue for the quarter was up 283.3% on a year-over-year basis. Equities research analysts expect that Intra-Cellular Therapies Inc. will post ($3.17) earnings per share for the current fiscal year.

Several hedge funds and institutional investors recently bought and sold shares of the company. Marshall Wace LLP boosted its position in Intra-Cellular Therapies by 23.5% in the fourth quarter. Marshall Wace LLP now owns 23,148 shares of the biopharmaceutical company’s stock valued at $1,245,000 after buying an additional 4,410 shares during the period. Rhumbline Advisers raised its stake in shares of Intra-Cellular Therapies by 33.1% in the fourth quarter. Rhumbline Advisers now owns 25,503 shares of the biopharmaceutical company’s stock valued at $1,372,000 after buying an additional 6,345 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Intra-Cellular Therapies by 505.4% in the fourth quarter. California Public Employees Retirement System now owns 78,700 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 65,700 shares in the last quarter. BlackRock Advisors LLC raised its stake in shares of Intra-Cellular Therapies by 1.7% in the fourth quarter. BlackRock Advisors LLC now owns 1,199,043 shares of the biopharmaceutical company’s stock valued at $64,497,000 after buying an additional 19,938 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Intra-Cellular Therapies by 212.9% in the fourth quarter. Jennison Associates LLC now owns 1,257,846 shares of the biopharmaceutical company’s stock valued at $67,660,000 after buying an additional 855,846 shares in the last quarter.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.